Medication, symptoms top concerns of Parkinson’s community: Survey
Foundation plans to use results to guide future education and programs
Written by |
-
Top concerns of the Parkinson's community's include disease symptoms and medication knowledge, a survey found.
-
Motor (tremor, gait, balance) and nonmotor (sleep, mood, cognitive) symptoms were most concerning.
-
Respondents cited the need more information on symptoms/treatments, better care access, and increased research funding.
According to this year’s Parkinson’s Foundation State of the Community Survey, disease symptoms and medication knowledge are top concerns for the Parkinson’s disease community.
More than half of the participants identified motor symptoms (61%), especially tremor, gait, and balance issues, and nonmotor symptoms (52%), including sleep, mood, and cognitive problems, as the most concerning.
Participants also expressed interest in learning more about the disease symptoms, treatment options, and research updates. The foundation plans to use these data to guide future education and programs.
“I believe in narrative medicine, where I encourage patients to share their Parkinson’s story — focusing on the symptoms [that] affect them the most and working together to create a personalized care plan that empowers them to take an active role,” Sneha Mantri, MD, Parkinson’s Foundation chief medical officer, said in a press release.
Barriers include lack of knowledge on available services
This year, more than 9,000 responders, mainly people with Parkinson’s (70%), but also care partners, family members, friends, and health professionals across the U.S. and other countries, participated in the survey in English or Spanish. This represents a 30% jump from 2025. The survey provides a global overview of the community’s experiences and needs, according to the foundation.
Another challenge reported by participants was understanding which questions to ask and symptoms to talk about with their healthcare team. Many considered it difficult to discuss mental and emotional health. Most people also noted only spending 15 to 30 minutes with their provider.
The most commonly reported barriers included a lack of knowledge on available services and how to access them, and difficulties getting appointments or having to travel long distances to get care. For Spanish speakers, barriers included service costs, language issues, and insufficient available services.
Also, one-quarter of participants went to the emergency room or were hospitalized in the previous year, but only 38% were aware of the Parkinson’s Foundation Hospital Safety Guide. The guide offers tools to help people with Parkinson’s advocate for the best care during hospitalization.
Additionally, while awareness of PD GENEration — an initiative offering free genetic testing and counseling to Parkinson’s patients in the U.S. — is increasing, only half of English speakers and 33% of Spanish speakers knew about the study. Among those aware and eligible for the study, about 60% of English speakers and 32% of Spanish speakers participated.
Participation in other studies was also low — 30% of English speakers and 18% of Spanish speakers. Reasons pointed out by survey responders for not participating in research included a lack of discussion from the care team and barriers related to eligibility, time, and traveling.
Participants also pointed out that exercise programs and mental health resources were lacking. Additionally, while digital tools may help with learning, managing symptoms, and care, many participants are unaware of these tools or do not know how to use them.
When asked which policy issues matter most, respondents cited increased research funding (48%), environmental risk factors (36%), access to care (32%), and pathways for treatment approvals (29%).
Overall, this survey shows that people want more trusted information about symptoms and treatment strategies, and many need more help getting care and support and preparing for a Parkinson’s appointment. Also, people need more tools to understand how to participate in research studies.
Gail
Meds?
Edmund T Keyes
I agree with the entire content of this Parkinson's News Today article. Thank you !!!
ANNE B BYRNE
Not mentioned was side effects of medication such as dyskinesia and the impact on socializing
Sandra Gilbert
My husband, 88, was diagnosed in February 2026. Came as a complete surprise. We , family members , we thought what was going on was part of getting older. I am reading as much as u can find and learning every day. I am 85. Daughter and son help out greatly.
David Revie
to many pop up come up making it difficult to get any info. Plus you seem to bombard me with info which I have trouble understanding.
Jan. Oliver
Wonderful, so badly needed. Whether the science ( genetics, hormonal or pharmaceutical) begins with broad discussion.
Anne Dix
It would be great to see how patients approach the expense on Medicare for Rytary and other drugs when they need access to extended release drugs and can't swallow. Currently my Dad pays 585 per month for Rytary which is prohibitively expensive. I would also like to know how patients are dealing with Medicare barriers with access to care. I find that people assume my Dad should go on hospice and off his meds constantly and I have to advocate strongly that we need palliative services such as PT and OT and Speech to keep him functional. It seems to be an uphill battle and that sharing speech and pt visits severely limits ability to provide my Dad with adequate support.